Your browser doesn't support javascript.
loading
Distinguishing features of long COVID identified through immune profiling.
Klein, Jon; Wood, Jamie; Jaycox, Jillian R; Dhodapkar, Rahul M; Lu, Peiwen; Gehlhausen, Jeff R; Tabachnikova, Alexandra; Greene, Kerrie; Tabacof, Laura; Malik, Amyn A; Silva Monteiro, Valter; Silva, Julio; Kamath, Kathy; Zhang, Minlu; Dhal, Abhilash; Ott, Isabel M; Valle, Gabrielee; Peña-Hernández, Mario; Mao, Tianyang; Bhattacharjee, Bornali; Takahashi, Takehiro; Lucas, Carolina; Song, Eric; McCarthy, Dayna; Breyman, Erica; Tosto-Mancuso, Jenna; Dai, Yile; Perotti, Emily; Akduman, Koray; Tzeng, Tiffany J; Xu, Lan; Geraghty, Anna C; Monje, Michelle; Yildirim, Inci; Shon, John; Medzhitov, Ruslan; Lutchmansingh, Denyse; Possick, Jennifer D; Kaminski, Naftali; Omer, Saad B; Krumholz, Harlan M; Guan, Leying; Dela Cruz, Charles S; van Dijk, David; Ring, Aaron M; Putrino, David; Iwasaki, Akiko.
Afiliação
  • Klein J; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Wood J; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Jaycox JR; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Dhodapkar RM; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Lu P; Department of Ophthalmology, USC Keck School of Medicine, Los Angeles, CA, USA.
  • Gehlhausen JR; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Tabachnikova A; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Greene K; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
  • Tabacof L; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Malik AA; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Silva Monteiro V; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Silva J; Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA.
  • Kamath K; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Zhang M; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Dhal A; SerImmune, Goleta, CA, USA.
  • Ott IM; SerImmune, Goleta, CA, USA.
  • Valle G; SerImmune, Goleta, CA, USA.
  • Peña-Hernández M; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Mao T; Department of Internal Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, New Haven, CT, USA.
  • Bhattacharjee B; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Takahashi T; Department of Microbiology, Yale School of Medicine, New Haven, CT, USA.
  • Lucas C; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Song E; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • McCarthy D; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Breyman E; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Tosto-Mancuso J; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.
  • Dai Y; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Perotti E; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Akduman K; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tzeng TJ; Abilities Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Xu L; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Geraghty AC; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Monje M; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Yildirim I; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Shon J; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Medzhitov R; Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA.
  • Lutchmansingh D; Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, CA, USA.
  • Possick JD; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Kaminski N; Yale Institute for Global Health, Yale School of Public Health, New Haven, CT, USA.
  • Omer SB; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.
  • Krumholz HM; Department of Pediatrics (Infectious Diseases), Yale New Haven Hospital, New Haven, CT, USA.
  • Guan L; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA.
  • Dela Cruz CS; SerImmune, Goleta, CA, USA.
  • van Dijk D; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
  • Ring AM; Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, USA.
  • Putrino D; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
  • Iwasaki A; Department of Internal Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, New Haven, CT, USA.
Nature ; 623(7985): 139-148, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37748514
Post-acute infection syndromes may develop after acute viral disease1. Infection with SARS-CoV-2 can result in the development of a post-acute infection syndrome known as long COVID. Individuals with long COVID frequently report unremitting fatigue, post-exertional malaise, and a variety of cognitive and autonomic dysfunctions2-4. However, the biological processes that are associated with the development and persistence of these symptoms are unclear. Here 275 individuals with or without long COVID were enrolled in a cross-sectional study that included multidimensional immune phenotyping and unbiased machine learning methods to identify biological features associated with long COVID. Marked differences were noted in circulating myeloid and lymphocyte populations relative to the matched controls, as well as evidence of exaggerated humoral responses directed against SARS-CoV-2 among participants with long COVID. Furthermore, higher antibody responses directed against non-SARS-CoV-2 viral pathogens were observed among individuals with long COVID, particularly Epstein-Barr virus. Levels of soluble immune mediators and hormones varied among groups, with cortisol levels being lower among participants with long COVID. Integration of immune phenotyping data into unbiased machine learning models identified the key features that are most strongly associated with long COVID status. Collectively, these findings may help to guide future studies into the pathobiology of long COVID and help with developing relevant biomarkers.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidrocortisona / Linfócitos / Herpesvirus Humano 4 / Células Mieloides / SARS-CoV-2 / Síndrome de COVID-19 Pós-Aguda / Anticorpos Antivirais Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hidrocortisona / Linfócitos / Herpesvirus Humano 4 / Células Mieloides / SARS-CoV-2 / Síndrome de COVID-19 Pós-Aguda / Anticorpos Antivirais Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos